Navigation Links
Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in,Phase III Pivotal Trial Compared to Neostigmine

OSS, the Netherlands, June 11, 2007-Sugammadex - the novel selective relaxant binding agent (SRBA) being developed by Organon, the human healthcare business unit of Akzo Nobel - demonstrated in a Phase III pivotal trial a 9-12 times faster reversal of neuromuscular blockade as compared to neostigmine, without evidence of post operative residual curarization (PORC) or re-occurrence of muscle relaxation.1, 2 The results of this pivotal Aurora trial were presented today at the 14th annual Euroanaesthesia 2007 congress in Munich, Germany.

The Aurora trial compared the efficacy of sugammadex and neostigmine for the reversal of shallow neuromuscular blockade induced by single or multiple doses of either rocuronium (Esmeron®/Zemuron®) or vecuronium (Norcuron®). “Sugammadex has shown a rapid and complete reversal in this pivotal trial without evidence of PORC or re-occurrence of neuromuscular blockade. Effective reversal is critically important to ensure that patients recover quickly and completely, without the risk of breathing difficulties,” commented one of the lead investigators involved in the Aurora trial, Professor M. Blobner from the Klinik für Anästhesiologie der Technischen Universität München, Germany. Reversal agents are used during general anesthesia to reverse the effects of muscle relaxants, also called neuromuscular blocking agents (NMBAs). Reversal of neuromuscular blockade is used to reduce the risk of PORC or re-occurrence of muscle relaxation. Phase III Trial Overview
The international, randomised, multicenter, parallel-group Aurora trial was conducted at 13 European centers and enrolled 198 patients. In the trial sugammadex was administered at reappearance of T2 and achieved significantly faster recovery of the T4/T1 ratio to 0.9 compared with neostigmine. Median time to recovery was 1.4 minutes (0.9-5.4; p<0.0001) for sugammadex versus 17.6 minutes (3.7-106.9; p<0.0001) for neostigmine foll
'"/>




Page: 1 2 3

Related medicine technology :

1. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
2. Organons Asenapine Effective in a Phase III Study for the Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA Meeting
3. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
4. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
5. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
6. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
7. Study Demonstrated Rozerem (ramelteon) Does Not Affect Middle-of-the-Night Balance in Older Adults with Insomnia
8. Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care
9. Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks
10. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
11. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival

Post Your Comments:
(Date:11/19/2009)...9 The D e al magazin...st Admired Corporate Dealmakers for the second con...ost Admired Dealmaker in pharma/biotech for the mo...estitures since January 2006. ,, Over the past ... with a focus on high-growth, innovation-driven bu...
(Date:11/19/2009)...Internet Week of Action ,, SILVER SPRING, Md.,...and Drug Administration today completed a coordina...ternational Internet Week of Action (IIWA), intend...cts. ,, (Logo: http://www.newscom.com/cgi-bin/...he FDA,s Office of Criminal Investigations (OCI), ...
(Date:11/19/2009)... Impliant, Inc., a developer of no...nal fusion surgery, announced today that it has ad... the Vice President of Clinical and Regulatory Aff...-bin/prnh/20080527/NETU060LOGO ) ,, Mr. Rolon...ence in the spinal and medical device field to Imp...
Breaking Medicine Technology:The Deal Names Abbott Top Dealmaker for Second Consecutive Year 2The Deal Names Abbott Top Dealmaker for Second Consecutive Year 3UPDATE: FDA Issues 22 Warning Letters to Web site Operators 2Impliant Announces the Addition of Vice President of Clinical and Regulatory Affairs to Executive Management Team 2Impliant Announces the Addition of Vice President of Clinical and Regulatory Affairs to Executive Management Team 3The Neutraceutical Company Announces Powerful New Feel Good Product 52215 1The Neutraceutical Company Announces Powerful New Feel Good Product 52215 2Stayhealthy and Innovative Wellness Solutions Announce Partnership to Bring Innovation to the Workplace Wellness Market 52211 1Stayhealthy and Innovative Wellness Solutions Announce Partnership to Bring Innovation to the Workplace Wellness Market 52211 2Stayhealthy and Innovative Wellness Solutions Announce Partnership to Bring Innovation to the Workplace Wellness Market 52211 3The Secrets to Staying Beautiful 3B Making the Most of Your Beauty Budget 52206 1The Secrets to Staying Beautiful 3B Making the Most of Your Beauty Budget 52206 2The Secrets to Staying Beautiful 3B Making the Most of Your Beauty Budget 52206 3
...g-Plough,Corporation (NYSE: SGP ) today reported ...ine, a fast-dissolving, sublingual tablet being,de...ffective than placebo,and well tolerated in treati...to the results, asenapine 5 mg twice daily and 10 ...ive than placebo at improving,patient Positive and...
... into Treatment Impact, Node-Positive ...D CITY, Calif., Dec. 17 Genomic Health,Inc. (Nasd...studies,reinforcing the clinical utility of the co...st to predict the likelihood of recurrence and the...rtion of early-stage,breast cancer patients. This ...
Other Medicine Technology:New Study Results Show Asenapine More Effective Than Placebo in the Treatment of Acute Schizophrenia 2New Study Results Show Asenapine More Effective Than Placebo in the Treatment of Acute Schizophrenia 3New Study Results Show Asenapine More Effective Than Placebo in the Treatment of Acute Schizophrenia 4Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R) 2Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R) 3Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R) 4Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R) 5Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R) 6Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R) 7
(Date:11/20/2009)...as 34 weeks, potentially adding to preemie deliver...(HealthDay News) -- Recent reports show that the r...e United States. Now, a new study suggests one re...itutes a full-term birth in the first place. , ...tudy considered a baby born at 34 to 36 weeks of g...
(Date:11/20/2009)...gh and is expected to continue, CDC says, , ...eas of the United States are seeing declines in H1...aid Friday, and while the disease remains widespre...ported last week. , "We are beginning to see so...ry, but there is still a lot of influenza everywhe...
(Date:11/20/2009)... Nov. 20 Missouri state employees ...s will now have the option to choose Mercy Health ...en Missouri Consolidated Health Care Plan (MCHCP) ...uth Central Missouri regions include the following...Dallas, Douglas, Greene, Hickory, Howell, Jasper, ...
(Date:11/20/2009)... Nov. 20 The Louisi...d that Louisianians could experience higher health...eing considered by Congress should become law. ,... for LAHP, "Louisiana health plans have supported ...ng of the national debate. Our plans have offered...
(Date:11/20/2009)...ov. 20 The US governmen...ggled to get enough food to eat. This startling s...ts who are rapidly aging into poverty. "Forced re...ivorce mean many have incomes that no longer cover... Older women are particularly vulnerable," said K...
Breaking Medicine News(10 mins):Health News:Many Women Miscalculate Time to Full-Term Birth 2Health News:Many Women Miscalculate Time to Full-Term Birth 3Health News:Many Women Miscalculate Time to Full-Term Birth 4Health News:Swine Flu Declining in Some Parts of U.S. 2Health News:Swine Flu Declining in Some Parts of U.S. 3Health News:Missouri Consolidated Health Care Plan Provides Mercy Health Plans Option 2Health News:Congressional Health Care Reform Proposals Would Make Health Care More Expensive, Reduce Benefits for Louisianians 2
...respiratory disease can walk further, and are less...e. Exercise is key to pulmonary// rehabilitation i...is to increase the distance they can walk in a fix...l effect of music when walking for such patients. ...
...ood coping style helps women to deal positively wi...r mental attitude makes a difference in the fight ...oking// at several studies and they conclude that ...to 44 per cent of women experienced anxiety and de...
... background of the surgeon does not affect the out... Glasgow have surveyed 4,139 melanoma patients who... They found the outcomes to be similar, whether th... breast surgeons generally get better results than...
...tins reduce the risk of heart attack in older peop...terol// levels and so lowers the risk of heart dis...-aged people, but the benefits for the elderly hav... of 4,050 men and women aged between 75 and 80 yea...
...susceptibility to lead is still a public health co...d over the past two decades. Previous studies hav... potential// cause for cancer, kidney disease, car...o mortality in the general population. Resea...
...atients and thereby recuperates their energy level...chemotherapy. It results from a decrease in levels... round the body. The problem with anaemia is that ... tasks. A new treatment, epoetin alfa, mimic...
Other Medicine News:
The Poncho Apron
MSP-3 Special Procedure wrap-around with Integrated Wide Belt
MSWB-1 Strap Apron with Wide Belt
MSV-10 Adjustable Velcro
Medicine Products: